Horizon Therapeutics

CG Results Healthcare has provided strategic support to Horizon Therapeutics resulting in the acquisition of a facility from EirGen Pharma

CG Results Healthcare is delighted to announce that it has provided strategic support to Horizon Therapeutics, a biotechnology company focused on rare, autoimmune diseases, that resulted in its acquisition of a drug product manufacturing facility from EirGen Pharma, in Ireland.

Under the terms of the agreement, Horizon will acquire the facility for a $65 million upfront cash payment. In addition, there is adjacent IDA land available for further manufacturing and development expansion. The transaction, which is subject to customary closing conditions, is expected to close in the third quarter.

This transaction is a testament to our deep sector knowledge and industry relationships.

Tim Walbert, chairman, president and chief executive officer, Horizon

“Adding to our strong network of contract manufacturing organizations, this facility will also play an important role in our global expansion. We look forward to leveraging our existing technical operations expertise in Ireland, along with the expertise of the EirGen employees, to build a robust and effective manufacturing operation that will enable us to meet the unmet needs of people impacted by rare diseases around the world.”